

1 **Title: Contrasting synaptic roles of MDGA1 and MDGA2**

2

3 Michael A. Bemben<sup>1</sup>, Matthew Sandoval<sup>2,3</sup>, Aliza A. Le<sup>2,3</sup>, Sehoon Won<sup>4</sup>, Vivian N. Chau<sup>2,3</sup>,  
4 Julie C. Lauterborn<sup>2,3</sup>, Salvatore Incontro<sup>1,5</sup>, Kathy H. Li<sup>6</sup>, Alma L. Burlingame<sup>6</sup>, Katherine W.  
5 Roche<sup>4</sup>, Christine M. Gall<sup>2,3</sup>, Roger A. Nicoll<sup>1,7,#</sup>, Javier Diaz-Alonso<sup>2,3,#</sup>.

6

7 <sup>1</sup> Department of Cellular and Molecular Pharmacology, University of California at San  
8 Francisco, San Francisco, CA 94158, USA.

9 <sup>2</sup> Department of Anatomy & Neurobiology, University of California at Irvine, CA, 92617, USA.

10

11 <sup>3</sup> Center for the Neurobiology of Learning and Memory, University of California at Irvine, CA,  
12 USA

13

14 <sup>4</sup> Receptor Biology Section, National Institute of Neurological Disorders and Stroke (NINDS),  
15 National Institutes of Health (NIH), Bethesda, MD, 20892, USA.

16 <sup>5</sup> Present address: Unité de Neurobiologie des canaux Ioniques et de la Synapse (UNIS),  
17 UMR1072, INSERM, Aix-Marseille University, Marseille, 13015, France.

18 <sup>6</sup> Department of Pharmaceutical Chemistry, University of California, San Francisco, San  
19 Francisco, CA 94158, USA.

20 <sup>7</sup> Department of Physiology, University of California at San Francisco, San Francisco, CA,  
21 94158, USA.

22 <sup>#</sup>, Correspondence should be addressed to roger.nicoll@ucsf.edu or jdiazalo@uci.edu

23 **Abstract**

24

25 Neurodevelopmental disorders are frequently linked to mutations in synaptic organizing  
26 molecules. MAM domain containing glycosylphosphatidylinositol anchor 1 and 2 (MDGA1 and  
27 MDGA2) are a family of synaptic organizers suggested to play an unusual role as synaptic  
28 repressors, but studies offer conflicting evidence for their localization. Using epitope-tagged  
29 MDGA1 and MDGA2 knock-in mice, we found that native MDGAs are expressed throughout  
30 the brain, peaking early in postnatal development. Surprisingly, endogenous MDGA1 was  
31 enriched at excitatory, but not inhibitory, synapses. Both shRNA knockdown and CRISPR/Cas9  
32 knockout of MDGA1 resulted in cell-autonomous, specific impairment of AMPA receptor-  
33 mediated synaptic transmission, without affecting GABAergic transmission. Conversely,  
34 MDGA2 knockdown/knockout selectively depressed NMDA receptor-mediated transmission but  
35 *enhanced* inhibitory transmission. Our results establish that MDGA2 acts as a synaptic repressor,  
36 but only at inhibitory synapses, whereas both MDGAs are required for excitatory transmission.  
37 This nonoverlapping division of labor between two highly conserved synaptic proteins is  
38 unprecedented.

39

40 **Teaser**

41

42 MDGAs 1 and 2 independently localize to and modulate excitatory and inhibitory hippocampal  
43 synapses by different mechanisms.

44 **Introduction**

45

46 The brain integrates and processes information via cell-to-cell communication at  
47 specializations between neurons termed synapses. Synapses link an individual neuron to a  
48 complex network of interconnected cells and facilitate the transfer of information in the form of  
49 excitation and inhibition. The balance and integration of excitatory and inhibitory synaptic  
50 transmission is required for proper brain function, as disruptions in these processes lead to  
51 neurological disorders such as epilepsy, autism spectrum disorders (ASDs), and schizophrenia  
52 (1-3). The assembly, maturation and maintenance of synapses are sustained by a multifarious  
53 network of proteins that organize and align the presynaptic release and postsynaptic receptor  
54 sites to allow for effective communication between neurons (4-6).

55

56 Similar to genetic alterations in other synaptic proteins that affect function, mutations in  
57 the memprin, A5 protein, receptor protein tyrosine phosphatase mu (MAM) domain containing  
58 glycosylphosphatidylinositol anchor (MDGA) family of proteins have been implicated in  
59 cognitive and psychiatric disorders, underscoring their critical importance in brain function (7-9).  
60 MDGAs are membrane-associated proteins that contain six tandem immunoglobulin (Ig)-like  
61 domains, a fibronectin-like region (FNIII), a single MAM domain, and a C-terminal  
62 glycosylphosphatidylinositol (GPI) anchor [Fig. 1A, B (10)]. The expression of MDGA proteins  
63 is restricted to the nervous system, begins early in development and continues throughout  
64 adulthood (11). Mammals have two highly conserved MDGAs, MDGA1 and MDGA2, which  
65 their dysfunction are associated, with schizophrenia and ASDs, respectively. (7-9). There is  
66 debate regarding the type of synapses each isoform localizes to due to lack of reliable anti-  
67 MDGA antibodies, inconclusive results in recombinantly expressed MDGA studies and  
68 inconsistency in the interpretation of knockdown experiments. Overexpressed YFP-MDGA1 and  
69 HRP-MDGA1 localizes to both excitatory and inhibitory synapses, as well as to extrasynaptic  
70 sites (12, 13). Similarly, HRP-tagged MDGA2 was found at inhibitory synapses (13) with no  
71 obvious concentration at excitatory, inhibitory, or extrasynaptic sites in another study (14).  
72 Similarly, a recent study found that expressed epitope-tagged MDGAs are highly mobile in the  
73 plasma membrane, with only a small fraction localizing at synapses (15). Despite these  
74 localization studies, functional readouts from overexpression studies have presumed MDGA

75 localization to postsynaptic sites (see discussion below). In stark contrast with overexpression  
76 studies, an elegant, *in situ* proximity-based proteomic characterization found endogenous  
77 MDGA1 and MDGA2 localized to excitatory and inhibitory postsynapses, respectively (13).  
78 Success in generating truly specific antibodies against MDGAs has been limited (16). However,  
79 a recent study reported the generation of a specific antibody against MDGA1 (15) and found a  
80 higher proportion of MDGA1 at excitatory synapses (40-45%) *vs* inhibitory synapses (20%) *in*  
81 *vitro*. Puzzlingly, this preference disappeared with neuronal culture maturation. Overall, these  
82 findings suggest that overexpressed and endogenous MDGAs localize differently, which is not  
83 uncommon for synaptic cell adhesion molecules.

84

85 Despite the lack of definitive subcellular localization, exogenous MDGA1 expression in  
86 cultured neurons has been shown to decrease inhibitory synapse number (12, 17, 18), whereas  
87 MDGA2 expression decreases excitatory and inhibitory synapse number and transmission (14).  
88 These results imply that MDGA1 is localized to inhibitory synapses, whereas MDGA2 is  
89 localized to both excitatory and inhibitory synapses, in contrast with reported localization of  
90 endogenous MDGAs (Loh *et al.*, 2016). But, most importantly, these results indicate that  
91 MDGAs are synaptic repressors, an unusual role for synaptic proteins. Consistent with this  
92 model, i) shRNA-mediated MDGA1 knockdown (KD) increases inhibitory synapse density and  
93 transmission in cultured neurons (12, 13, 17) – although this has been recently challenged by  
94 studies which find no specific change in inhibitory synaptic transmission upon MDGA1 deletion  
95 in cultured and hippocampal CA1 neurons (15, 18), and ii) MDGA2 KD/knockout (KO) leads to  
96 a specific increase in excitatory transmission (15) – although another group found that it does not  
97 result in a specific change in either excitatory or inhibitory synapse number (13). MDGA1 KO  
98 mice are viable with no gross anatomical phenotypes, but have an imbalance of  
99 excitation/inhibition (19, 20). In contrast, the MDGA2 KO is lethal in mice (a striking phenotype  
100 for an individual synaptic protein), which has hampered its study (14).

101

102 MDGA's synaptic repressor function is thought to rely on their ability to modulate  
103 transsynaptic neuroligin-neurexin interactions, thereby interfering with a core molecular  
104 substrate of synapse formation and maintenance (4, 16, 21). Consistent with cell adhesion and  
105 surface bindings assays (12, 17), multiple independent groups have provided robust MDGA –

106 neurologin co-crystal structural data suggesting that MDGAs can sterically block access of  
107 neurexins to neurologins (22-24). However, this model is primarily based on exogenous  
108 overexpression of MDGAs, and despite the reported high affinity of the interaction between  
109 MDGA1 and neurologin-2 (Nlgn2), it remains unclear whether these proteins share overlapping  
110 spatial or temporal expression to interact *in vivo* (25). It is noteworthy that individual neurologin  
111 KOs are not lethal, suggesting that MDGA2, at least in part, performs neurologin-independent  
112 functions. Finally, unbiased proteomic screens have not identified MDGAs as binders to  
113 neurologin, also challenging the model (26).

114

115 In summary, previous findings suggest that MDGAs can act as synaptic repressors, and  
116 have at least partially non-overlapping expression in the brain, but there is not a single unified  
117 model that can incorporate all of the field's findings. Critically, the endogenous localization and  
118 role of MDGA proteins remains undefined. Here, we systematically address two fundamental  
119 and unresolved questions in the field: i) are endogenous MDGAs primarily synaptic repressors  
120 acting through neurologins? and ii) what are the endogenous (spatial and temporal) localization  
121 of MDGA1 and MDGA2? Our results show that MDGA1 and MDGA2 expression overlap  
122 temporally and spatially in the developing mouse brain. In agreement with its expected role as  
123 synaptic repressor, we found that loss of function of MDGA2 results in increased synaptic  
124 transmission, although, contrary to expectations, only at inhibitory synapses. Surprisingly, we  
125 found that both MDGA1 and MDGA2 are required for excitatory synaptic transmission, with an  
126 unprecedented segregation of tasks for a family of synaptic proteins: while MDGA1 contributes  
127 exclusively to AMPAR- mediated transmission, MDGA2 selectively supports NMDAR-  
128 mediated transmission. Using a combination of techniques, primarily focusing on endogenous  
129 MDGAs in the Schaffer collateral (SC)-CA1 pyramidal neuron (PN) synapse, we describe  
130 unrecognized roles for MDGA1 and MDGA2 controlling excitatory and inhibitory synaptic  
131 transmission by distinct mechanisms in the mouse hippocampus.


132 **Results**

133

134 **Temporal and anatomical distribution of native MDGA proteins.**

135 Where are endogenous MDGA1 and MDGA2 expressed? To reliably assess the temporal and  
136 spatial expression patterns of endogenous MDGA1 and MDGA2, we generated epitope-tagged  
137 knock-in (KI) mouse lines. Specifically, we generated hemagglutinin (HA)-tagged MDGA1 mice  
138 (Fig. 1A, Fig. S1) and Myc-tagged MDGA2 mice (Fig. 1B, Fig. S2). A series of steps were taken  
139 to ensure consistency with the literature and to provide confidence that the tags would not alter  
140 the function of MDGAs: i) we inserted small tags (8-10AAs) in the N-terminal of the proteins to  
141 minimize the likelihood of altering protein folding, trafficking and/or function given that  
142 previous work with fluorescently tagged MDGAs showed widespread localization in dendrites  
143 and axons (12); ii) we specifically used HA-tag for MDGA1 and Myc-tag for MDGA2 in the  
144 same locations as the commonly used overexpression constructs in the field; and iii) throughout  
145 the manuscript we focused the characterization of native MDGAs at hippocampal CA1 PN,  
146 given that both MDGA1 and MDGA2 are expressed in CA1 PNs [Mouse Whole Cortex and  
147 Hippocampus SMART-seq [2019]] with 10x-SMART-seq taxonomy (2021), (14, 19, 20)]. First,  
148 we validated the specificity of the HA-MDGA1 and Myc-MDGA2 signal using Western blots  
149 [WB, (Fig. 1C-H)]. Bands were detected at approximately 130 KDa, slightly above the expected  
150 molecular weight of MDGA1 and MDGA2, yet consistent with recent reports and likely due to  
151 prominent glycosylation (15). These bands were absent from wild-type (WT) samples and  
152 considered specific. Using HA-MDGA1 / Myc-MDGA2 and WT mice, we characterized the  
153 expression of the MDGAs across postnatal developmental stages focusing on six different time  
154 points, from postnatal day 3 (P3) to P130. The expression of both native MDGAs is strongly  
155 developmentally regulated, with a peak around P14 and more modest expression extending into  
156 adulthood (Fig. 1C-F). We next assessed the regional distribution across different brain regions  
157 at P15. We detected high expression of MDGA1 in areas largely consistent with previous *in situ*  
158 hybridization data (17) and  $\beta$ -galactosidase activity in  $Mdga1^{+/lacZ}$  mice (19) (Fig. 1G). Myc-  
159 MDGA2 expression followed a similar pattern (Fig. 1H), also consistent with previous  
160 estimations of MDGA2 expression using  $\beta$ -galactosidase activity in  $Mdga2^{+/lacZ}$  mice (14).  
161 Immunofluorescence confirmed that native MDGA1 is highly expressed in the areas identified  
162 with WB, displaying particularly high expression in the hippocampus (Fig. 1I-K).

# Figure 1



**Fig 1. Native MDGA1 and MDGA2 expression in the postnatal mouse brain.** A, B, Schematic of the epitope-tagged HA-MDGA1 (A) and Myc-MDGA2 (B). C, D, Representative immunoblot of HA-MDGA1 and Myc-MDGA2 expression in the mouse brain, respectively, from postnatal day 3 to postnatal day 130, using  $\alpha$ -tubulin as a loading control. WT P14 sample included for antibody specificity control. E, F, Quantification of HA-MDGA1 /  $\alpha$ -tubulin and Myc-MDGA2 /  $\alpha$ -tubulin ratios, respectively, normalized to postnatal day 3 values in the KI mice. P14 (peak HA-MDGA1 and Myc-MDGA2 expression) samples from WT mice were used as a control of tag antibody specificity. G, H, Representative immunoblots of HA-MDGA1 and Myc-MDGA2, respectively, using  $\alpha$ -tubulin as a loading control, across brain regions. n=3-4 mice/condition for all Western blot analyses. I, Representative HA-MDGA1 immunofluorescence staining in coronal (top panel) and sagittal (bottom panel) slices of HA-MDGA1 mice at P15. J, Representative confocal images of HA staining with DAPI in WT (top) and HA-MDGA1 (bottom) of P20 HA-MDGA1 KI mouse hippocampus. High magnification insets of area CA1 are shown to the right. K, Quantification of HA puncta from high magnification confocal images shown in J ( $p<0.001$ , n=8 mice/genotype). Bar graphs represent mean  $\pm$  SEM. \*,  $p<0.005$ ; \*\*,  $p<0.01$ ; \*\*\*,  $p<0.001$ , one-way ANOVA (E, F), unpaired two-tailed Student's T-Test (K). Scale bars: I, 1 mm. J, 200  $\mu$ m, insets: 50  $\mu$ m. "SR", stratum radiatum; "SP", stratum pyramidale; "SO", stratum oriens.

164 **Synaptic localization of MDGA1.**


165 MDGA proteins are considered synaptic adhesion molecules (16, 25, 27). However,  
166 while some reports have provided evidence of synaptic expression of endogenous MDGAs (13),  
167 single molecule imaging studies on overexpressed MDGAs suggest a diffuse localization within  
168 dendrites (15). Therefore, we set out to determine if MDGA1 is expressed at synapses, and  
169 whether it preferentially localizes to excitatory or inhibitory synapses. Based on the  
170 developmental time-course of MDGA1 expression (Fig. 1C, E), we initially co-labelled P15  
171 brain samples for HA-MDGA1 together with excitatory or inhibitory synaptic markers. We  
172 focused on hippocampal area CA1, which shows high expression both at the mRNA (17) and  
173 protein levels (Fig. 1). Using confocal microscopy, we detected a punctate distribution of HA-  
174 MDGA1 in strata radiatum (SR) and oriens (SO), whereas the density of HA-MDGA1 puncta  
175 was minimal in stratum pyramidale [SP, (Fig. 1J, K)].

176


177 These findings indicate that native MDGA1 displays a punctate, synapse-like distribution in  
178 CA1, with a laminar distribution consistent with a bias towards excitatory synapses. To directly  
179 test this prediction, we evaluated MDGA1 localization in CA1 SR, which includes excitatory  
180 CA3 (SC)-CA1 PN synapses as well as inhibitory synapses impinging on dendritic shafts. To  
181 determine whether native MDGA1 localizes at excitator

## Figure 2

### Distribution of MDGA1 at excitatory vs inhibitory postsynaptic compartments



### Distribution of MDGA1 at excitatory vs inhibitory presynaptic compartments



**Fig 2. HA-MDGA1 is enriched in excitatory synaptic compartments in the stratum radiatum of the mouse hippocampal area CA1.** A, Low magnification (left) and high magnification (right) representative confocal immunofluorescence images labeling DAPI, HA-MDGA1, and either excitatory (Homer1b/c, top panels) or inhibitory (NLGN2, bottom panels) postsynaptic marker in P20 HA-MDGA1 mouse hippocampi. B, Quantification of the colocalization of high intensity HA-MDGA1 and synaptic marker puncta (within 5  $\mu$ m of each other) in the SR. The number of colocalized HA puncta is higher in HA-MDGA1 than WT with Homer1b/c ( $p < 0.0001$ ), but not with NLGN2 ( $p = 0.2219$ ). In HA-MDGA1 samples, the proportion of HA-MDGA1 puncta colocalized with Homer1b/c is higher than with NLGN2 ( $p < 0.0003$ ), whereas in WT samples it is not ( $p = 0.9981$ ). C, D, In the MDGA1-HA/Homer1b/c colocalization experiment, the number of HA puncta was higher in KI samples ( $p < 0.0001$ , C), but the number of Homer1b/c was not different

( $p=0.7481$ , D). E, F, in the HA-MDGA1/Nlgn2 colocalization experiment, the number of HA puncta was higher in KI samples ( $p=0.0004$ , E), but the number of Nlgn2 was not ( $p=0.4332$ , F). G, Low magnification (left) and high magnification (right) representative confocal immunofluorescence images labeling DAPI, HA-MDGA1, and either excitatory (vGluT1, top panels) or inhibitory (vGAT, bottom panels) presynaptic marker in P20 HA-MDGA1 mouse hippocampi. H, Quantification of the colocalization of high intensity HA-MDGA1 and synaptic marker puncta (within 5  $\mu$ m of each other) in the SR. The number of colocalized HA puncta is higher in HA-MDGA1 than WT ( $p = 0.0012$  with vGluT1,  $p = 0.049$  with vGAT). In neither HA-MDGA1 samples ( $p = 0.0958$ ) nor in WT samples ( $p=0.9981$ ) the proportion of HA-MDGA1 puncta colocalized with vGluT1 and vGAT are significantly different. I, J, In the MDGA1-HA/vGluT1 colocalization experiment, the number of HA puncta was higher in KI samples ( $p<0.0001$ , I), and the number of vGluT1 was not ( $p= 0.9033$ , J). K, L, in the HA-MDGA1/vGAT colocalization experiment, the number of HA puncta was higher in KI samples ( $p= 0.0029$ , K), but the number of vGAT was not ( $p= 0.1157$ , L).  $n = 5/8$  mice/group. Bar graphs represent mean  $\pm$  SEM. n.s., non-statistically significant; \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ , Two-way ANOVA followed Tukey's post hoc test in B and H and unpaired T-test in C-F and I-L. Scale bars: Left panels: 200  $\mu$ m. Right panels: 20  $\mu$ m. "SR", Stratum RADIATUM.

183 by synapses, we co-labeled P15 HA-MDGA1 and WT samples with HA and the excitatory  
184 postsynaptic marker Homer1b/c. Using fluorescence tomography based on three-dimensional  
185 (3D) reconstructions of individual HA-MDGA1 puncta alongside the excitatory post-synaptic  
186 puncta created from image z-stacks, we examined the colocalization of MDGA1 with Homer.  
187 We then performed a similar analysis with the postsynaptic inhibitory synaptic marker Nlgn2,  
188 previously shown to interact with MDGA1 (12, 17, 22-24), (Fig. S3A). Counts of the double  
189 labeled synapses indicate that native MDGA1 is enriched at excitatory Homer1b/c-  
190 immunoreactive (ir) postsynapses, compared with inhibitory Nlgn2-ir postsynapses (Fig. S3A,  
191 B). We then assessed colocalization of MDGA1 with markers for the presynaptic element at  
192 excitatory and inhibitory synapses, vGluT1 and vGAT, respectively. Quantification of double-  
193 labeled puncta again indicated a preferential localization of HA-MDGA1 to excitatory  
194 presynaptic elements (Fig. S3G, H). Despite the presence of some HA immunolabeling in WT  
195 samples, the number of HA-ir puncta was substantially higher in KI samples (Fig. S3C, E, I, K),  
196 whereas numbers of elements immunoreactive for synaptic markers did not differ between  
197 genotypes (Fig. S3D, F, J, L). We then performed 3D reconstructions using confocal z-stacks  
198 from the SR using P20 mice, which exhibit substantial MDGA1 expression and have more  
199 mature synapses, and quantified the number of HA-MDGA1 puncta overlapping with excitatory  
200 and inhibitory postsynaptic markers (Fig. 2A, B) and presynaptic markers (Fig. 2G, H). Using  
201 this approach, the number of HA-ir puncta was several-fold higher in HA-MDGA1 samples

202 compared with WT counterparts (Fig. 2C, E, I, K), while the number of synaptic marker puncta  
203 was not significantly different between genotypes (Fig. 2D, F, J, L). Among the HA-MDGA1  
204 puncta localized at postsynapses, we found a greater number of puncta localized in Homer1b/c-ir  
205 excitatory compartments, compared with Nlgn2-labelled inhibitory compartments (Fig. 2B). In  
206 contrast, we found a non-significantly higher number of MDGA1 associated with the excitatory  
207 presynaptic marker vGluT1 than with the inhibitory marker vGAT. Together, our findings  
208 indicate that native MDGA1 is preferentially expressed at excitatory synapses, although, despite  
209 the punctate pattern of expression found for native MDGA1, a substantial proportion of MDGA1  
210 was not found to colocalize with the synaptic markers analyzed here.


211

## 212 **Synaptic localization of MDGA2.**

213 Our KI strategy enables MDGA2 protein detection via WB, allowing for detection of  
214 MDGA2 protein in mouse brain for the first time, which constitutes a significant advance in the  
215 field (Fig. 1D, F, H). Unfortunately, we were unable to identify conditions for Myc-MDGA2  
216 localization using immunofluorescence. Thus, we turned to an unbiased proteomics screen to  
217 decipher the landscape surrounding MDGA2 to provide insights into its localization.  
218 Immunoprecipitated MDGAs were exposed to solubilized mouse forebrain lysates to perform an  
219 unbiased proteomic analysis (Fig. 3A). Synaptic proteins were enriched with both MDGA1 and  
220 MDGA2. Consistent with our previous findings, excitatory synaptic proteins, such as Leucine-  
221 rich repeat transmembrane neuronal 1 (LRRTM1), are enriched in the MDGA1 proteome,  
222 whereas we identified proteins found in both excitatory [e.g., NMDA receptor (NMDAR)  
223 subunit GluN1], and inhibitory synapses (such as Nlgn2) in the MDGA2 proteome (Fig. 3B,  
224 supplementary Table 1 for a full list of MDGA1 and MDGA2 interacting proteins). The binding  
225 between MDGA2 and GluN1 has not been previously reported, and therefore wondered if this  
226 may be a direct interaction. We found that MDGA2 and GluN1 can directly interact in  
227 heterologous cells and confirmed that MDGA2 binds to GluN1 with higher affinity than  
228 MDGA1 (Fig. 3C), mirroring the finding that GluN1 is enriched in the MDGA2, but not the  
229 MDGA1, proteome. Next, we tested whether NMDAR subunit composition affects the  
230 preference of binding to MDGA2 *vs* MDGA1 and found that both GluN1/GluN2A (Fig. 3D) and  
231 GluN1/GluN2B (Fig. 3E) complexes interact preferentially with MDGA2 over MDGA1, with

## Figure 3


A




B

MDGA1 Binding Proteins	
Accession	Gene Name or Symbol
Q3TQ54	beta-neurexin 2D4
P15388	K voltage-gated channel subfamily C member 1
Q8K377	Leucine-rich repeat transmembrane neuronal 1
P11627	Neural cell adhesion molecule L1
MDGA2 Binding Proteins	
Accession	Gene Name or Symbol
Q3TQ54	beta-neurexin 2D4
P15388	K voltage-gated channel subfamily C member 1
P35438	N-methyl-D-Aspartate Receptor Subunit NR1
Q6ZK9	Neuroligin-2
Q3TPU9	Astrotactin-1


C



D



E



232

**Fig 3. Unbiased screen to identify MDGA1 and MDGA2 interacting proteins identifies isoform-specific interactions between MDGA proteins and NMDAR subunits.** A, Five-step process to identify MDGA interacting proteins. (1) MDGA1 or MDGA2 were expressed in HEK293T cells and treated with phospholipase C (PLC) to release the MDGAs from the membrane. (2) Immunoblot analysis of transfected HA-MDGAs ± PLC showing a reduction in cell lysate and an increase in cell media of MDGAs following PLC treatment. (3) MDGAs were precipitated from the Media with an HA-Ab. (4) Purified MDGAs were incubated with solubilized brain lysate. (5) Interacting proteins were visualized with silver staining and identified using mass spectrometry. Arrows indicate MDGA1 and MDGA2 respectively. B, List of representative MDGA1 and MDGA2 interacting proteins that were pulled down in at least 2 of 3 experiments (see Supplementary Table 1 for the complete list). Yellow highlight indicates association with both MDGA1 and MDGA2. Blue highlight indicates proteins exclusively found to interact with MDGA2 either found previously in the literature or confirmed with co-IP.

C, co-IP of overexpressed Flag-tagged GluN1 subunit of the NMDAR with HA-tagged MDGA1/2 in HEK293T cells. Quantification is shown to the right. Interaction with MDGA2 is of approximately 3-fold higher affinity than MDGA1 ( $p<0.001$ ). D, co-IP of overexpressed Flag-tagged GluN2A subunit of the NMDAR together with the obligatory GluN1 subunit with HA-tagged MDGA1/2 in HEK293T cells. Quantification is shown to the right. Both GluN2A and GluN1 interact with MDGA2 with higher affinity than with MDGA1 ( $p=0.0037$  and  $p=0.0092$ , respectively). E, co-IP of overexpressed Flag-tagged GluN2B subunit of the NMDAR together with the obligatory GluN1 subunit with HA-tagged MDGA1/2 in heterologous HEK cells. Quantification is shown to the right. Both GluN2B and GluN1 interact with MDGA2 with higher affinity than with MDGA1 ( $p<0.0001$  and  $p=0.0105$ , respectively).  $n=3$  for all experiments. \*,  $p<0.05$ ; \*\*,  $p<0.01$ ; \*\*\*,  $p<0.001$  (Student's T-test). "WB", Western blot; "Ab", antibody.

233 GluN1/GluN2A receptors showing stronger preference. Lastly, we assessed whether the GluN1  
234 subunit is necessary for MDGA2-NMDAR interaction and found that both GluN2A and GluN2B  
235 can interact with MDGA2 independently of GluN1 (Fig. S4). Collectively, these data support  
236 MDGA2 localization at both excitatory and inhibitory synapses.

237

### 238 **The role of MDGAs in excitatory synaptic transmission.**


239 Our present results, together with those of others, indicate that MDGAs localize, at least  
240 in part, to synapses. However, their role in synaptic transmission is controversial. We therefore  
241 examined the physiological consequences of deleting MDGA1 and MDGA2 either individually  
242 or together (to control for the potential for functional redundancy due to their high sequence  
243 homology) on excitatory and inhibitory synaptic transmission. CA1 PNs express MDGAs [Figs.  
244 1 and 2, (14, 20)], thereby constituting an ideal cell type to elucidate their cell-autonomous role  
245 in synaptic transmission.

246

247 We initially confirmed that the MDGA shRNAs (13) selectively reduce MDGA protein  
248 (Fig. 4A). To explore the physiological role of MDGA proteins on excitatory synaptic  
249 transmission, we biolistically transfected shRNAs targeting MDGA1 and MDGA2 into  
250 organotypic hippocampal slice cultures, which results in sparse transfection of a few CA1 PNs  
251 per slice. AMPA receptor (AMPAR)- and NMDAR-mediated EPSCs, evoked with a stimulating  
252 electrode placed in SR, were simultaneously measured in a KD cell and a neighboring, non-  
253 transfected control CA1 PN was held at -70 mV and +40 mV, respectively (Fig. 4B-C). The  
254 simultaneous KD of MDGA1 and MDGA2 decreased both AMPAR and NMDAR mediated

255 currents by approximately 50% (Fig. 4D). To assess whether MDGA1 or MDGA2 alone  
 256 accounted for these effects, we performed individual KD of each protein. MDGA1 KD alone was

## Figure 4



**Fig 4. Knockdown of MDGA family decreases excitatory currents.** A, Immunoblot analysis of HA-MDGAs transfected with MDGA1, MDGA2, or control shRNA in HEK cells. B, Experimental timeline. C, Dual whole-cell recording setup in organotypic hippocampal rat slices. Black and green filled neurons represent untransfected (control) and transfected (experimental) neurons, respectively. D, AMPAR ( $p=0.0049$ ,  $n=12$ )- and NMDAR ( $p=0.0005$ ,  $n=13$ )-mediated EPSC scatter plots displaying reductions in MDGA1,2 KD transfected cells compared to control cells. Open circles are individual pairs, filled circle is mean  $\pm$  SEM. Representative traces show control (black) and transfected (green) neurons.

Bar graphs plot transfected amplitude normalized to control cell  $\pm$  SEM. E, AMPAR ( $p=0.0010$ ,  $n=13$ )- and NMDAR ( $p>0.05$ ,  $n=12$ )-mediated EPSC scatter plots displaying a selective reduction in only AMPAR-mediated EPSC amplitudes in MDGA1 KD transfected cells compared to control cells. F, AMPAR ( $p>0.05$ ,  $n=11$ )- and NMDAR ( $p=0.008$ ,  $n=10$ )-mediated EPSC scatter plots displaying a selective reduction in only NMDAR-mediated EPSC amplitudes in MDGA2 KD transfected cells compared to control cells. \*\*,  $p<0.01$ ; \*\*\*,  $p<0.001$ , Wilcoxon signed-rank test. Scale bar for D-F: 25pA, 0.1s. “WB”, Western blot; “Ab”, antibody; “DG”, dentate gyrus.


257 sufficient to recapitulate the impairment in AMPAR EPSCs caused by the dual deletion, while  
258 leaving NMDAR EPSCs unaffected (Fig. 4E). Conversely, MDGA2 KD reproduced the decrease  
259 in NMDAR EPSCs found in the dual KD, while leaving AMPAR currents unaltered (Fig. 4F).  
260 These findings indicate that MDGA1 and MDGA2 are essential for excitatory synaptic  
261 transmission in the SC-CA1 PN synapse and selectively modulate AMPAR- and NMDAR-  
262 mediated currents, respectively. Strikingly, these results are the opposite of what one would  
263 expect if MDGAs are synaptic repressors.

264

## 265 **Role of MDGAs in inhibitory synaptic transmission.**

266 We explored the effect of combined KD of MDGA1 and MDGA2 in inhibitory synaptic  
267 currents (Fig. 5A). Cells lacking both MDGA1 and MDGA2 exhibited enhanced inhibitory  
268 postsynaptic currents (IPSCs, Fig. 5D), with the individual KD of MDGA2 (Fig. 5F), but not  
269 MDGA1 (Fig. 5E), selectively increasing inhibitory currents. These findings are consistent with  
270 a role for MDGAs as synaptic repressors at inhibitory synapses, yet this effect is confined to  
271 MDGA2, and not to MDGA1 as previously suggested (12, 17, 18, 20). Having identified a  
272 synaptic repressor role for MDGA2, we tested whether repressor function is mediated via the  
273 interaction with Nlgn2 which we identified using unbiased proteomics (Fig. 3B). To do so, we  
274 mutated the phenylalanine and tyrosine amino acids in positions 149 and 150 of MDGA2 with  
275 alanine (FY149-150AA), thereby blocking the previously found interaction with Nlgn2 (24). We  
276 first demonstrated that expressing a shRNA-resistant version of MDGA2 (Fig. 5B, C) fully  
277 reverses the enhancement of IPSCs seen in the KD (Fig. 5H). Conversely, expression of the  
278 FY149-150AA mutant together with the MDGA2 shRNA resulted in a robust enhancement of  
279 IPSCs (Fig. 5I) underscoring that the repressor function is dependent on the neuroligin  
280 interaction.

## Figure 5



281

**Fig 5. Knockdown of MDGA2 increases inhibitory currents in a neuroligin-dependent manner.** A, Experimental timeline. B, Immunoblot analysis of HA-MDGA2 or HA-MDGA2\* (shRNA resistant plasmid) transfected with MDGA2 or control shRNA in HEK cells. C, Total MDGA2 lysate levels (means  $\pm$  s.e.m.) normalized to control show efficient MDGA2 KD against HA-MDGA2 ( $p=0.0286$ ,  $n=4$ ), but not HA-MDGA2\* ( $p>0.9999$ ). D, Scatter plots showing enhancements in IPSC-mediated currents in MDGA1,2 KD transfected cells compared to untransfected control cells ( $p=0.0009$ ,  $n=14$ ). Open circles are individual pairs, filled circle is mean  $\pm$  s.e.m. Black sample traces are control, green are transfected neurons. Bar graphs plots transfected amplitude normalized to control cell  $\pm$  s.e.m. E, Scatter plots showing no significant difference in IPSC-mediated currents in MDGA1 KD transfected cells compared to untransfected control cells ( $p>0.05$ ,  $n=14$ ). F, Scatter plots showing enhancements in IPSC-mediated currents in MDGA2 KD transfected cells compared to untransfected control cells ( $p=0.002$ ,  $n=10$ ). G, Scatter plots showing no significant difference in IPSC-mediated currents in MDGA2 overexpressing (OE) transfected cells compared to untransfected control cells ( $p>0.05$ ,  $n=12$ ). H, Scatter plots showing no significant difference in IPSC-mediated currents in MDGA2 KD + MDGA2\* OE transfected cells compared to untransfected control cells ( $p>0.05$ ,  $n=9$ ). I, Scatter plots showing

enhancements in IPSC-mediated currents in MDGA2 KD + MDGA2\* FY149-150AA OE transfected cells compared to untransfected control cells ( $p=0.0391$ ,  $n=9$ ). IPSC amplitudes recorded at 0 mV. \*,  $p<0.05$ ; \*\*,  $p<0.01$ ; \*\*\*,  $p<0.001$ , Mann-Whitney U test (C), Wilcoxon signed-rank test (D-I). Scale bar for D-I: 100 pA and 0.05 s. “WB”, Western blot. “Ab”, antibody.

## 282 **Role of MDGAs in dendritic spine morphology.**

283 Anatomically, co-expression of the shRNAs for MDGA1 and MDGA2 did not change  
284 spine density in CA1 PNs nor did it alter the spine head diameter (Fig. S5A-D), although it  
285 caused a significant reduction in neck length and an increase in neck diameter (Fig. S5E, F).  
286 Thus, MDGA proteins appear to play a role in regulating spine neck morphology, thereby  
287 potentially regulating biochemical and electrical spine compartmentalization and signaling (28,  
288 29).


289

## 290 **Synaptic effects of overexpressing MDGAs.**


291 Our results are provocative because they appear to contradict previous findings, many of  
292 which were obtained using overexpression of MDGAs. First, our data show a dramatic  
293 functional specificity of MDGA1 and MDGA2 at excitatory and inhibitory synapses and, second,  
294 while the action of MDGA2 at inhibitory synapses confirms the synaptic repressor role, the  
295 action of MDGA1 at excitatory synapse is fundamentally different. To resolve these apparent  
296 contradictions, we carried out experiments using overexpression of MDGAs. Remarkably,  
297 overexpression of MDGA1 (Fig. S6A, B) *reduced* both AMPAR and NMDAR EPSCs (Fig.  
298 S6C), thus indicating that overexpressed MDGAs behave as synaptic repressors, as expected  
299 from previous reports. A limitation of overexpression experiments is that high levels may cause  
300 protein mistargeting and ultimately “gain-of-function” for the examined protein, a reasonable  
301 possibility for MDGAs given the difference seen in endogenous *vs.* exogenous localization  
302 studies [see figures above, (12, 13, 15, 17)]. To address this concern, we inserted an internal  
303 ribosomal entry site (IRES) sequence upstream of the MDGAs cDNA (Fig. S6A-B), a strategy  
304 which limits protein expression (30, 31). Consistent with previous findings (17), but in contrast  
305 with MDGA2 overexpression (Fig. 5G), we found that both strong (Fig. S7A) and mild (Fig.  
306 S7B) MDGA1 overexpression causes a marked reduction of IPSCs. These findings are consistent  
307 with MDGA1 acting as a synaptic repressor at inhibitory synapses. Given previous reports  
308 suggesting that MDGA1 function requires interaction with Nlgn2 (12, 17), we tested whether an

## Figure 6


A




B



C



D



309

**Fig 6. CRISPR knockout of MDGA family increases inhibitory and decreases excitatory currents.** A, Immunoblot analysis of HA-MDGAs transfected with MDGA1, MDGA2, or control CRISPRs in HEK cells. B, Total MDGA lysate levels (means  $\pm$  SEM) normalized to control show efficiency of MDGA1 CRISPR #1 ( $p=0.0035$ ,  $n=5$ ) and MDGA1 CRISPR #2 ( $p=0.0328$ ,  $n=5$ ), and MDGA2 CRISPR #1 ( $p=0.0065$ ,  $n=5$ ). C, Scatter plots showing enhancements in IPSC-mediated currents in MDGA1,2 KO transfected cells compared to untransfected control cells ( $p=0.0020$ ,  $n=10$ ). Open circles are individual pairs, filled circle is mean  $\pm$  SEM. Black sample traces are control, green are transfected neurons. Scale bar denotes 100 pA and 0.05 s. Bar graphs plots transfected amplitude normalized to control cell  $\pm$  SEM. D, AMPAR ( $p=0.0010$ ,  $n=12$ )- and NMDAR ( $p=0.0156$ ,  $n=9$ )-mediated EPSC scatter plots displaying reductions in MDGA1,2 KO transfected cells compared to control cells. Scale bar denotes 25 pA and 0.1 s. Bar graphs as in C. \*,  $p<0.05$ ; \*\*,  $p<0.01$ ; \*\*\*,  $p<0.001$ , Mann-Whitney U test (B), Wilcoxon signed-rank test (C-E). “WB”, Western blot; “Ab”, antibody.

310 interaction between MDGA1 and Nlgn2 was required for the MDGA1 overexpression-induced  
 311 reduction in synaptic transmission. Interestingly, we found that overexpressing the MDGA1  
 312 FY147-148AA mutant that lacks the Nlgn2-binding motif results in AMPAR and NMDAR  
 313 EPSCs being as strongly decreased as with WT MDGA1 overexpression (Fig. S6E), while it no  
 314 longer affects IPSCs (Fig. S7C). These findings indicate that neuroligin interaction is required  
 315 for the depressive effect of MDGA1 overexpression, yet only at inhibitory synapses.

316 **CRISPR/Cas9 deletion of MDGAs.**

317 Our findings indicate that both endogenous MDGAs support excitatory synaptic  
318 transmission and that MDGA2 acts as a repressor of inhibitory synaptic transmission. However,  
319 manipulations involving shRNAs can have off-target effects (32). Therefore, to verify our  
320 shRNA results we used an alternative genetic deletion approach, based on sparse CRISPR/Cas9-  
321 mediated KO in organotypic hippocampal slices (33). We designed several gRNAs against the  
322 MDGAs, tested their KO efficiency, and selected the best for further evaluation (Fig. 6A, B).  
323 Using an analogous experimental strategy as the one utilized in our shRNA KD experiments, we  
324 analyzed the effect of the dual MDGA1/2 CRISPR on synaptic transmission. This alternative  
325 method resulted in an increase in IPSCs (Fig. 6C), and a reduction in AMPAR- and NMDAR-  
326 EPSCs (Fig. 6D). These results are indistinguishable from those obtained with the shRNA  
327 approach, thus solidifying our conclusion that MDGAs act as synaptic repressors only at  
328 inhibitory synapses and are facilitators of synaptic transmission at excitatory synapses.

329 **Discussion**

330

331 The formation, maintenance, and activity-dependent modification of synapses is  
332 orchestrated by a multitude of synaptic adhesion molecules, commonly referred to as “synaptic  
333 organizers” (4). Broadly, synaptic organizers perform two functions: inducing the assembly of  
334 new synapses or specifying synapse properties (27). The recent proposal that MDGAs act as  
335 synapse repressors suggests an additional, perhaps underappreciated layer of synapse regulation.  
336 While there are multiple adhesion molecules that have been demonstrated to positively influence  
337 synapse formation, MDGAs are receiving substantial attention as negative regulators, a role only  
338 few other synaptic proteins have been shown to play (34-36). Elucidating the endogenous  
339 functions of MDGAs has not been a trivial task, as simply localizing MDGAs to the synapse has  
340 not been straightforward.

341

342 Ten years after the first reports of the synaptic roles of MDGAs (12, 17), the precise  
343 cellular localization and role of endogenous MDGAs remains enigmatic. Similar to other  
344 synaptic cell adhesion molecules, the function(s) of MDGAs were initially defined largely based  
345 on overexpression studies (12, 13, 17) although, taken together, these studies underscore the  
346 difficulties in interpreting overexpression experiments. Perhaps this is particularly the case for  
347 MDGAs because of their lack of intracellular domains allowing direct anchoring to excitatory  
348 (i.e. through MAGUKs) or inhibitory (i.e. through gephyrin/collybistin) synapses, making them  
349 more prone to mislocalization when overexpressed. *In situ* hybridization and  $\beta$ -galactosidase  
350 reporter experiments confirm that the MDGA1 and MDGA2 are expressed in neurons (11, 17,  
351 37) (14, 19, 20). Proximity-based proteomic assessment of endogenous MDGA localization  
352 found that MDGA1 was localized to excitatory synapses, while MDGA2 was localized to  
353 inhibitory synapses in cultured neurons (13). Additionally, KD strategies have been used to gain  
354 insight on the physiological role of MDGA proteins. Several reports (12, 13, 17) found increases  
355 in inhibitory synapse density in dissociated neuronal cultures after MDGA1 KD, establishing the  
356 prevailing view that MDGA1 acts primarily to negatively regulate inhibitory synapses. In  
357 contrast, more recent KO studies challenge this notion reporting that i) deletion of MDGA1 does  
358 not alter inhibitory synapse number or transmission (18) and ii) loss of either MDGA isoform did  
359 not affect IPSCs (15). In sum, although there is general consensus in the field that MDGAs can

360 act as synaptic repressors, these seemingly divergent sets of results constrain the formation of an  
361 integrative model of MDGA synaptic function.

362

363 Therefore, when we set out to elucidate their function, it was imperative to establish their  
364 subcellular localization. We generated epitope-tagged MDGA1 and MDGA2 KI mice to  
365 circumvent technical limitations with MDGA antibodies. Our results represent a breakthrough in  
366 the study of endogenous MDGA2, by allowing the detection of the endogenous protein by  
367 immunoblot. We uncovered that both MDGA proteins are widely expressed throughout the CNS  
368 and follow a very marked developmentally regulated expression pattern. Specifically, the  
369 chronological and regional expression pattern of MDGA1 and MDGA2 are largely overlapping  
370 (noteworthy given they do not appear to have overlapping synaptic functions), with a peak of  
371 expression around the 2<sup>nd</sup>-3<sup>rd</sup> weeks of postnatal life. Remarkably, our imaging data provide the  
372 first direct evidence of the enrichment of MDGA1 at SC-CA1 PN synapses in the hippocampus  
373 and indicates that endogenous MDGA1 is expressed, at least in part, at young excitatory  
374 synapses *in vivo*. Intriguingly, we identify the existence of a significant pool of MDGA1 which  
375 is not at excitatory or inhibitory synapses, as previously suggested (15). This potentially non-  
376 synaptic pool of MDGA1 is deserving of future exploration. Disappointingly, our genetic  
377 approach did not allow for imaging of MDGA2 in intact brain tissue. However, our proteomics,  
378 biochemistry, and electrophysiology data are consistent with previous proteomic analyses of  
379 endogenous MDGA2 localization (13), and deem it likely that MDGA2 is present at both  
380 excitatory and inhibitory synapses onto hippocampal CA1 PNs. Interestingly, few postsynaptic  
381 cell adhesion molecules are shared by excitatory and inhibitory synapses. To the best of our  
382 knowledge, neuroligin-3 (NLGN3) is the only other exception to the rule (38). Unlike NLGN3,  
383 MDGA2 plays fundamentally different roles at each synapse type, acting as a repressor at  
384 inhibitory synapses but supporting NMDAR transmission at excitatory synapses, again  
385 highlighting the uniqueness of the synaptic roles played by MDGA2.

386

387 The disparate results seen for MDGA KD between neuronal cultures and *in vivo*  
388 experiments coupled with emerging evidence that synaptic organizers can have different roles at  
389 different synapse types, we performed all the physiology experiments on a well-defined  
390 preparation and synapse type (SC→CA1 PN synapse in mouse hippocampal slices) to mitigate

391 these confounding factors. We found that the individual KD of MDGA1 and MDGA2 cell-  
392 autonomously and selectively decreases AMPAR- and NMDAR-mediated currents, respectively.  
393 We are not aware of another family of synaptic organizers with such diverse roles at the same  
394 synapse. Conversely, eliminating MDGAs from neurons enhanced IPSCs, an effect entirely  
395 mediated by MDGA2 deletion, supporting our proposal that endogenous MDGA2 acts as a  
396 repressor of IPSCs. Together with our imaging, proteomics and biochemistry data, these results  
397 provide converging evidence for the localization of MDGA1 at excitatory synapses, and of  
398 MDGA2 at both excitatory and inhibitory synapses. These findings are largely consistent with  
399 the endogenous localization study of Loh *et al.* (13), and with the notion that MDGAs act as  
400 repressors at inhibitory synapses (12, 16, 17). Provocatively, these data show that, in contrast to  
401 what had previously been suggested (14, 15), MDGAs do not act as repressors of excitatory  
402 synapses and have a fundamentally different role in maintaining EPSCs.

403

404 Albeit through a fundamentally different mechanism to the previously proposed, our  
405 results are largely consistent with findings using MDGA KO mice. For example, the decreased  
406 E/I ratio found in MDGA1 KO mice can be explained by an increase of inhibitory synapses, as  
407 suggested previously (20) but also by a decrease in excitatory transmission (present study). The  
408 altered LTP and learning in MDGA1 KOs can be explained by the reduced AMPAR trafficking  
409 or function found in our study. Similarly, the reported increase in AMPAR/NMDAR ratio in the  
410 MDGA2 heterozygotes (the homozygous KO is lethal), previously associated with an increase in  
411 AMPAR levels (14) is also consistent with a specific decrease in NMDAR EPSCs reported  
412 herein. The impaired NMDAR function could conceivably also influence the deficits in LTP and  
413 hippocampal-dependent learning and memory found in the MDGA2 heterozygotes (14).  
414 Interestingly, our KD studies revealed a previously unrecognized role of MDGA proteins  
415 regulating dendritic spine morphology, which may also contribute to the MDGA KO mice  
416 phenotype. Specifically, MDGA1/2-lacking spines have significantly shorter and wider spine  
417 necks. Alterations in spine morphology are linked with numerous neurological disorders  
418 including schizophrenia and ASD, two disorders with which MDGA1 and MDGA2 are  
419 associated, respectively (39).

420

421 Previous reports indicate that MDGA1's function depends on the modulation of  
422 neuroligin-neurexin interactions (12, 15, 17, 22-24). However, our study failed to find a  
423 functional relationship between endogenous MDGA1 and Nlgn2. Specifically, we did not find i)  
424 an effect of MDGA1 KD in IPSCs, ii) a co-distribution of MDGA1 at Nlgn2-positive puncta in  
425 the mouse brain, and iii) Nlgn2 enriched in the unbiased MDGA1 proteome. This is consistent  
426 with a recent report which suggested that, rather than neuroliginss, MDGA1 function requires its  
427 interaction with presynaptic amyloid precursor protein [APP, (18)]; although, to note, APP was  
428 not found in our immunoprecipitation studies (Supplementary Table 1). We did find that  
429 exogenous MDGA1 expression leads to decreased IPSCs, in accord with previous reports (12,  
430 17, 22). However, these overexpression data, including our own, are inconsistent with MDGA1  
431 KD/KO data in which deleting MDGA1 has no effect on synaptic inhibition [present study, (15,  
432 18)]. Therefore, we conclude that overexpression approaches have led to substantial confusion  
433 about synaptic MDGA localization, perhaps through "gain of function" effects by mistargeting  
434 of the protein to non-endogenous synapses, a possibility consistent with our finding that the  
435 repressive effect of MDGA1 overexpression at inhibitory synapses is abrogated by mutations  
436 that diminish binding with Nlgn2, a protein endogenous MDGA1 likely does not share spatial  
437 proximity with but with which it may interact when overexpressed (Fig. S7).

438

439 Instead, we found that, in addition to NMDAR-mediated EPSCs, MDGA2 controls  
440 inhibitory synaptic transmission. Interestingly, a MDGA2 mutant with impaired interaction with  
441 Nlgn2 did not rescue IPSCs in a MDGA2 KD background, in contrast with the full rescue  
442 achieved with WT MDGA2. This finding is consistent with the MDGA2-Nlgn2 interaction  
443 revealed in our unbiased proteomics. Altogether, our results challenge the model where MDGA1  
444 acts as a specific gatekeeper of inhibitory synapse formation and/or function (20, 21, 25) and are  
445 consistent with a more prominent role at excitatory synapses. Our findings instead indicate that  
446 the gatekeeper of inhibitory synapses is MDGA2, which likely involves the regulation of Nlgn2.  
447 Furthermore, we uncovered that MDGA2 is required for NMDAR function. We found that both  
448 the obligatory GluN1 subunit and the GluN2A and GluN2B subunits can directly bind MDGA  
449 proteins independently, and that they show a preference for MDGA2 vs MDGA1 in a co-  
450 immunoprecipitation assay, again an intriguing result given their high sequence conservation.  
451 However, the finding that only GluN1 is represented in the MDGA2 proteome from native

452 mouse brain tissue indicates that this subunit may play the predominant role in the MDGA2-  
453 NMDAR interaction *in vivo*. This raises an interesting scenario in which two different synaptic  
454 MDGA2 pools coexist, one specialized in regulating NMDAR (neuroligin-independent) and  
455 another dedicated to modulate GABAergic transmission (neuroligin-dependent).

456

457 How do MDGAs contribute to excitatory synaptic transmission? The elegant structural  
458 studies on the MDGA/neuroligin complex (22-24) provide a molecular explanation for our  
459 finding that MDGA2 acts as a synaptic repressor at inhibitory synapses. In contrast, the  
460 mechanisms underlying the action of MDGAs at excitatory synapses remain uncertain. As  
461 described above, MDGAs lack transmembrane or intracellular domains, which typically direct  
462 synaptic targeting. Therefore, they are likely to rely on extracellular protein-protein interactions  
463 for their synaptic localization, which presumably underlies their relatively low synaptic  
464 localization compared to other synaptic proteins [our data, (15)]. The interaction between  
465 MDGA2 and NMDAR thus conceivably involves extracellular NMDAR motifs, which are  
466 critical for receptor trafficking and function (40). Similarly, recent work has established a  
467 prominent role for extracellular domains for synaptic AMPAR localization (41-43). These  
468 findings suggest that extracellular interactions with synaptic cleft proteins, including synaptic  
469 adhesion molecules such as MDGA1, may regulate AMPAR trafficking and function (6, 44).  
470 Although we did not find a direct interaction between AMPARs and MDGA1, we did find that  
471 LRRTM1 was found specifically in the MDGA1 proteome. This is noteworthy for several  
472 reasons. First, this protein specifically promotes AMPAR transmission without affecting  
473 NMDAR function (45), mimicking MDGA1's role. Second, the LRRTM proteins were used as  
474 the "bait" which unbiasedly and indirectly localized MDGA1 at excitatory synapses (13). Third,  
475 as with MDGA1, LRRTM1 is associated with schizophrenia (46). Collectively, the relationship  
476 between LRRTMs and MDGAs remains an exciting area of future exploration. Notably, even  
477 after MDGAs bind to neuroligins via their Ig1 and Ig2 domains, they still retain large interacting  
478 surfaces and are likely poised for other potential molecular interactions. The most intriguing  
479 candidates from our proteomics work suggest those may happen in *cis* like neuroligins (GluN1,  
480 LRRTM1); however, our unbiased approach also pulled out synaptic proteins like neurexins  
481 which would presumably interact in *trans* across the synapse, an exciting avenue of future  
482 exploration.

483                   Summarily, our study provides the first subcellular localization data of endogenous  
484 MDGA1 in brain tissue and establishes that MDGA proteins play essential, yet highly divergent  
485 roles at different synapse types. Future directions will include learning how MDGA1 and  
486 MDGA2 control AMPAR and NMDAR transmission, as well as explore the role of MDGA  
487 proteins in other brain circuits as identified by the expression of MDGAs found in our KI mice.  
488 The overall theme to emerge from our work is that MDGAs do not perform a unitary function  
489 (i.e., repressors) at synapses. Instead, the different MDGA family members play unique and  
490 complex roles in shaping transmission at excitatory and inhibitory synapses.

491

492 **Materials and Methods**

493

494 **Animals**

495 All animal procedures were approved by the Institutional Animal Care and Use  
496 Committees at the University of California, San Francisco (protocol number AN183289, PI,  
497 Roger Nicoll) and University of California, Irvine (protocol number AUP-20-156, PI, Javier  
498 Diaz-Alonso). All animals were maintained in 12 hour (h) light/dark schedule and with access to  
499 food and water, *ad libitum*.

500

501 Generation of HA-MDGA1 and Myc-MDGA2 mouse strains was performed by Cyagen Inc. by  
502 CRISPR/Cas9 mediated homology-directed repair (Fig. S1A and Fig. S2A). Briefly, the gRNA  
503 to mouse *Mdga1* gene (5'-CCCTTCCACTGTCGGGGACAAGG-3'), the donor oligo containing  
504 the HA-tag-RSRD linker (5'-TACCCATACGATGTTCCAGATTACGCTAGATCTCGAGAT-  
505 3') flanked by 120 nt homology arms combined on both sides and Cas9 mRNA were coinjected  
506 into fertilized mouse eggs to generate targeted knock-in (KI) offspring. F0 founder animals were  
507 identified by PCR followed by sequence analysis, and bred to WT mice to test germline  
508 transmission and F1 animal generation. At least 5 backcrossings were performed before using the  
509 animals for experiments to minimize the possible artifacts caused by non-specific insertions. An  
510 analogous procedure was followed for Myc-MDGA2, using the gRNA 5'  
511 TCCACTCACCGTACACTCCTTGG-3' and the Myc-tagged-RSRD linker 5'-  
512 GAACAAAAACTCATCTCAGAAGAGGATCTGAGATCTCGAGAT-3'.

513

514 Validation of the successful KI was achieved by genotyping PCR (performed by  
515 TransnetYX, Inc.), genomic sequencing (Figs. S1B, S2B), Western blot, and  
516 immunofluorescence. The predicted protein sequences after successful recombination are  
517 indicated in Fig. S1C and Fig. S2C, respectively. After backcrossing, both colonies were  
518 maintained in homozygosity and a HA-MDGA1/Myc-MDGA2 colony was created and used for  
519 most of the experiments in this paper. Postnatal day (P) 3-130 HA-MDGA1/Myc-MDGA2 mice  
520 of either sex were used in this study.

521

522 P6-8 (Sprague Dawley) rat pups of either sex were employed to generate the organotypic  
523 hippocampal slice cultures employed in MDGA overexpression, shRNA-mediated MDGA KD  
524 and CRISPR/Cas9-mediated MDGA KO experiments.

525

## 526 **Constructs**

527 Rat pCAG-HA-MDGA1, Mouse pCAG-HA-MDGA2 (generous gift from Ann Marie  
528 Craig's Laboratory, University of British Columbia), pCAG-HA-MDGA2\* (shRNA resistant),  
529 pCAG-HA-MDGA1 FY147-148AA, pCAG-HA-MDGA2\* FY149-150AA, pCAG-mCherry-  
530 IRES-HA-MDGA1, pCAG-mCherry, GluN1-GFP (generous gift from Stephen Traynelis's  
531 laboratory, Emory University) were used for biochemical and electrophysiology experiments.

532 The primers used to create MDGA2\* were forward 5'-

533 AGTATAGGCGAGGCCAAGGAGCAGTTTAC - 3' and reverse 5'-

534 GTAAAAGTGCCTGGCCTCGCCTATACT- 3', MDGA1 FY147-148AA were forward 5'-

535 GCGACGTCCGAGGCAACGCCGCCAGGAGAAGACCGTGT - 3' and reverse 5'-

536 ACACGGTCTTCTCCTGGCGGCCGTTGCCTCGGACGTCGC- 3', MDGA2 FY149-150AA

537 were forward 5'- TATAGGCGAGGCCAAGGAGCAGGCTGC

538 CTATGAGAGAACAGTGTTCCTC - 3' and reverse 5'- GAGGAACACTGTTCTCTCA

539 TAGGCAGCCTGCTCCTGGCCTCGCCTATA- 3', IRES-HA-MDGA1 were forward 5'-

540 CTTGCCACAACCCGGGATGGATGTCTCTCTTGCCTC - 3' and reverse 5'-

541 CTCGAGCTAGCGGCCGCTCATCTCTGCAACGCCAAGA- 3', IRES-HA-MDGA2 were

542 forward 5'- CTTGCCACAACCCGGGATGGATGTCTCTCTTGCCTC - 3' and reverse 5'-

543 CTCGAGCTAGCGGCCGCTCACCTCGAGGGCTTAAGA- 3'. pLLs-anti MDGA1 and

544 pLLs-anti MDGA2, which dually express GFP for positive transfection identification (generous

545 gifts from Alice Ting's Laboratory, Stanford University), knockdown (KD) constructs were used

546 for electrophysiology and imaging. Knockout (KO) constructs used for electrophysiology and

547 biochemistry were MDGA1 KO CRISPR #1 (sequence: TCCGGGAGAGCGACACCCTG)

548 MDGA1 KO CRISPR #2 (sequence: GACGGTACAGCGTAGAAACA), MDGA1 KO CRISPR

549 #3 (sequence: GATAAAGCGGGCGGGCGGGT), MDGA2 KO CRISPR #1 (sequence:

550 AGCAATAAAGTCGATCCGAG), MDGA2 KO CRISPR #2 (sequence:

551 ACTCGGATCGACTTATTGC), and MDGA2 KO CRISPR #3 (sequence:

552 TACAGTAATATCGGCCTCCT). The CRISPR constructs were generated using a standard

553 PCR cloning procedure that included fusing antisense primers and subcloning into a lentiviral  
554 vector that expressed Cas9 and GFP. The primers used to create MDGA1 KO CRISPR #1 were  
555 forward 5'- CACCGCAGGGTGTGCTCTCCCGA – 3' and reverse 5'-  
556 AAACTCCGGAGAGCGACACCCTGC – 3', MDGA1 KO CRISPR #2 were forward 5' –  
557 CACCGACGGTACAGCGTAGAAACA – 3' and reverse 5'-  
558 AAACTTTCTACGCTGTACCGTC – 3', MDGA1 KO CRISPR #3 were forward 5' -  
559 CACCGATAAAGCGGGCGGGCGGGT – 3' and reverse 5'-  
560 AACACCCGCCCGCCGCTTATC – 3', MDGA2 KO CRISPR #1 were forward 5'-  
561 CACCGAGCAATAAGTCGATCCGAG – 3' and reverse 5'- AACACCTCGGATCGAC  
562 TTTATTGCTC – 3', MDGA2 KO CRISPR #2 were forward 5' - CACCGACTCGGAT  
563 CGACTTTATTGC – 3' and reverse 5'- AACAGCAATAAGTCGATCCGAGTC – 3',  
564 MDGA2 KO CRISPR #3 were forward 5' – CACCGTACAGTAATATCGGCCTCCT – 3' and  
565 reverse 5'- AACAGGAGGCCGATATTACTGTAC- 3.

566

### 567 **Cell culture and transfections**

568 HEK293T cells (ATCC) were grown and maintained in DMEM (Gibco, 11966025)  
569 supplemented with 10% fetal bovine serum [FBS (Hyclone, SH30071.03)] and 1% glutamine  
570 (Gibco, 25030081) without antibiotic in a humidified incubator at 37°C with 5% CO<sub>2</sub>. For  
571 biochemistry, transfections were performed directly after splitting the cells in 6-well plates using  
572 Lipofectamine 2000 Reagent (Invitrogen, 11668019) following the manufacturer's instructions.  
573 Briefly, 1.5 µg of total DNA (for protein expression analyses) or 2 µg GluN1, 2 µg HA-MDGAs,  
574 and 4 µg GluN2A or 2B (for Co-IPs), were mixed with Lipofectamine at a 1:1 ratio in 100 µL of  
575 pre-warmed Opti-MEM (Gibco, 31985062) for 15 minutes (min) at room temperature (RT). The  
576 resulting mixture was added to an individual well of a 6-well plate. When GluN2A or 2B was co-  
577 transfected with GluN1, 50 µM AP-5 and 20 mM MgCl<sub>2</sub> were added 4 hours (hr) after  
578 transfection. 24-48 h post transfection, cells were washed and collected in ice-cold PBS and  
579 centrifuged.

580

### 581 **Co-immunoprecipitation and immunoblotting**

582 For Western blot, after centrifugation, pelleted cells were lysed with 200 µL of 4x SDS-  
583 PAGE sample buffer, sonicated, denatured for 5 min at 65°C, and centrifuged at 20,000 x g for 5

584 min to pellet insoluble cellular debris. Protein lysates (5  $\mu$ L or 2.5% of sample, avoiding the  
585 pelleted debris) were separated by SDS-PAGE. For more details see (47).

586

587 For co-IP, after centrifugation, cell pellets were resuspended in 1% Triton X-100 lysis  
588 buffer and lysed for 1 hr at 4°C. Protein lysates were collected after centrifugation. Then, the HA  
589 antibody (Cell Signaling #3724) was added to lysates and incubated overnight at 4°C. Next day,  
590 protein A Sepharose (Sigma-Aldrich #P3391) was added to the mixture and incubated for 4 hr at  
591 4°C. The Protein A Sepharose-attached antibody-protein complexes were washed with 1% Triton  
592 X-100 lysis buffer 3 times. 2X SDS sample buffer was added to the complexes and incubated at  
593 42°C for 20 min for protein elution. The eluted proteins were separated with 7% SDS-PAGE.

594

595 WT and HA-MDGA1/Myc-MDGA2 brain tissue was processed as previously described  
596 (48). Briefly, either the entire forebrain or dissected brain regions, were collected in ice-cold  
597 PBS and homogenized in buffer containing 20 mM Tris-HCl (pH 7.5), 0.32 M sucrose (Millipore  
598 Sigma, 573113), 5 mM EDTA (Sigma-Aldrich, 6381-92-6) and protease and phosphatase  
599 inhibitors (Roche, #11836170001). After centrifugation at 1,000g for 10 min to remove the  
600 nuclear fraction, the supernatant (S1) was either mixed with SDS-containing sample buffer or  
601 centrifuged at 10,000g for 15 min to obtain the P2 fraction. The P2 fraction was then re-  
602 suspended in SDS-containing sample buffer.

603

604 All samples were assessed by PAGE-SDS electrophoresis. Immuno-Blot® PVDF  
605 membranes (Bio-Rad, #1620177) were blocked with 5% blotting grade nonfat milk (Lab  
606 Scientific, #M0841) in tris buffered saline buffer with 0.1% tween 20 (Sigma-Aldrich, #P1379).  
607 The following primary antibodies (company, cat no.) were used in Western blot experiments:  
608 mouse anti-beta-actin (ABM, #G043), mouse anti-Flag (Sigma, #F1804), mouse anti-GluN1  
609 (Thermo #32-0500), mouse anti-HA (Roche, #11 867 423 001), rabbit anti-HA (Cell Signaling,  
610 #3724), rabbit anti-Myc (Abcam, #ab9106), mouse anti- $\alpha$ -tubulin (Sigma-Aldrich, #T9026).  
611 HRP-conjugated secondary antibodies raised against the appropriate species were used: anti-  
612 mouse IgG (GE Healthcare, #NA931), anti-rabbit IgG (GE Healthcare, #NA934), anti-rat IgG  
613 (Cell Signaling Technology, #7077), Anti-Rabbit IgG (Vector laboratories #PI-1000), anti-  
614 mouse IgG (Vector laboratories #PI-2000). Clarity™ Western ECL (BioRad, #170-5060) was

615 then added to membranes. Western blots were imaged using BioRad Chemidoc. Blot images  
616 were analysed by creating a uniformly sized box around each desired band, leaving room above  
617 and below. A histogram measuring the band intensity across the length of the box was created. A  
618 level base for the histogram was then approximated, encompassing an area containing the lowest  
619 signal point to the highest signal point. The area of the resulting triangle was then measured via  
620 the FIJI (Image J, Janelia) software. To represent the developmental time-course of MDGA  
621 expression, HA-MDGA1 /  $\alpha$ -tubulin and Myc-MDGA2 /  $\alpha$ -tubulin ratios were calculated and  
622 normalized to a reference age (P3). All data are presented as mean  $\pm$  SEM.

623

#### 624 **Immunofluorescence**

625 For immunofluorescence analyses, 4% paraformaldehyde (PFA) fixed coronal or sagittal  
626 brain slices (30  $\mu$ m thick) were processed. After blocking tissue with 5% swine serum and 2%  
627 BSA in permeabilizing conditions (0.1% Triton X-100, Sigma-Aldrich, # T8787),  
628 immunofluorescence was performed by overnight incubation at 4 °C with a rabbit anti-HA  
629 primary antibody (Cell Signaling, #3724, 1:500 dilution), in combination with one of four  
630 primary guinea pig antibodies against synaptic markers: Homer1b/c (Synaptic Systems, #160  
631 025, 1:200), Nlgn2 (Synaptic Systems, #129 205, 1:500), vGluT1 (Synaptic Systems, #135 304,  
632 1:15,000), vGAT (Synaptic Systems, #129 205, 1:500). This was followed by incubation with  
633 corresponding Alexa 488 goat anti-guinea pig (Invitrogen, #A-11073, 1:500) and Alexa 594 goat  
634 anti-rabbit (Invitrogen, #A-11012, 1:500) secondary antibodies. Slides were mounted with either  
635 Vectashield Antifade Mounting Medium with DAPI (Vector Laboratories, # H-1200) or ProLong  
636 Gold Antifade Reagent with DAPI (Cell Signaling Technology, # 8961S).

637

#### 638 **Fluorescence Tomography microscopy and quantification**

639 Image z-stacks of hippocampal field CA1 stratum radiatum (SR) were collected at 0.2  
640  $\mu$ m steps using a 1.4 NA 63X objective on a Leica DM6000 epifluorescence microscope  
641 equipped with a Hamamatsu ORCA-ER digital camera. The image sample field size was 105 x  
642 136 (x,y) with a 2  $\mu$ m depth (z), for a total size of 28,560  $\mu$ m<sup>3</sup>. For each antisera combination, 6-  
643 8 image stacks from three sections per brain were taken. On average, the total numbers of  
644 synaptic profiles assessed per image stack in the P15 brain were: 9,715  $\pm$  1,236 (s.e.) for Homer,  
645 6,515  $\pm$  325 for Nlgn2, 16,950  $\pm$  1,651 for vGluT1, and 10,674  $\pm$  280 for vGAT. The greater

646 number of excitatory versus inhibitory synaptic profiles at this age is consistent with previous  
647 work showing greater asymmetric versus symmetric shaft synapses on CA1 stratum pyramidale  
648 (SP) neurons (Watson et al. 2016).

649

650 For quantification of immunofluorescent-labeled puncta, image stacks were pre-  
651 processed by standardizing the dynamic range via inserting two high and two low intensity  
652 reference squares (100x100 pixels;  $1\mu\text{m}^2$ ) to the green and red channels of all images (Python  
653 3.8 with NumPy, skimage.io, os, PIL, tifffile, and json). This step allows the subsequent  
654 quantification of all puncta intensity to be normalized to the global reference square intensity for  
655 each channel, rather than the maximum intensity within the image, without largely altering the  
656 background or existing raw pixel values. Image stacks were then analyzed using in-house  
657 software to quantify double-labeled, single-labeled, and all-labeled puncta within the size  
658 constraints of synapses as previously described (49-52). Background staining variations in the  
659 deconvolved images were normalized to 30% of maximum background intensity using a  
660 Gaussian filter. Object recognition and measurements of immunolabeled puncta were automated  
661 using software built in-house using Matlab R2019b, Perl, and C which allows for detailed  
662 analysis of objects reconstructed in 3 dimensions (3D). Pixel values (8-bit) for each image were  
663 multiply binarized using a fixed-interval intensity threshold series followed by erosion and  
664 dilation filtering to reliably detect edges of both faintly and densely labeled structures. Object  
665 area and eccentricity criteria were applied to eliminate from quantification elements that do not  
666 fit the size and shape range of synaptic structures, including the global reference squares. For  
667 synaptic compartment localization of the HA-tag, immunolabeled puncta were considered  
668 colocalized if they touched or overlapped to any degree as assessed in 3D. Immunolabeled object  
669 counts were averaged across sections to produce mean values for each measure per animal.

670

## 671 **Confocal Imaging and Image Analysis**

672 Brain sections were imaged with a Leica Sp8 confocal microscope (Leica Microsystems,  
673 Wetzlar, Germany) equipped with six single photo laser lines (405 nm, 458, 488, 514, 568, and  
674 633 nm) and four detectors at the University of California, Irvine Optical Biology Core. Images  
675 were acquired using a 63x oil objective as a series of 20 z-steps, with a z-step size of  $1.38\mu\text{m}$ , at  
676 a resolution of  $1024 \times 1024$  pixels, scanning frequency of 400 Hz. The optical resolution (voxel

677 size) per image was 180 nm in the xy-plane and 1.38  $\mu\text{m}$  in the z-plane. Images were saved in a  
678 “lif.” format, and analysis and quantification of total synaptic puncta and puncta colocalization  
679 was performed using Imaris 9.9.1 (Bitplane, South Windsor, CT, USA) and MatLab Runtime  
680 R2022b (Mathworks, Natick, MA, USA).

681

682 Imaris analysis entailed a software-specific conversion of the original “lif.” file into an  
683 “ims.” format, allowing for three-dimensional analysis. The new “ims.” file contained both the  
684 original image and its stored metadata. Generally, the “Spots” tool was utilized to assign  
685 representative three-dimensional ellipsoid shapes to cover individual puncta. This included  
686 puncta of each of the four synaptic markers (Homer1b/c, Nlgn2, vGluT1, and vGAT) as well as  
687 HA-MDGA1. These spots were then used as a proxy for synaptic puncta during further  
688 colocalization analysis and quantification. Once in Imaris, the brightness and contrast settings for  
689 CH2 (HA-MDGA1, Alexa 594) and CH3 (Synaptic marker, Alexa 488) were adjusted to  
690 qualitatively minimize background noise in each channel and emphasize specific signal. These  
691 settings were then applied across all KI and WT images. When creating the “spots” for HA-  
692 MDGA1 and each of the synaptic markers, the following protocol was followed. First, the  
693 minimum xy and z diameters of HA-MDGA1 puncta were set to 0.5  $\mu\text{m}$  and 0.9  $\mu\text{m}$ ,  
694 respectively. The same was done with dimensions of 0.4  $\mu\text{m}$  in the xy-plane and 0.9 in the z-  
695 plane for the synaptic markers Homer1b/c, Nlgn2, and vGAT, and 0.5  $\mu\text{m}$  and 0.9  $\mu\text{m}$  in the xy-  
696 and z-planes, respectively, for vGluT1. The “Background Subtraction” option available when  
697 creating spots was then used. Technically, this option smooths the image prior to the addition of  
698 spots by using a Gaussian filtered channel (Gaussian filtered by  $\frac{3}{4}$ ) minus the intensity of the  
699 original channel Gaussian filtered by 8/9th of the punctum radius. A region of interest (ROI) was  
700 created to restrict the colocalization quantification to solely within SR of each image. This ROI  
701 spanned an average area of approximately  $15,9812 \pm 1506 \mu\text{m}^2$  across all samples. When building  
702 the corresponding representative spots, the number of spots were adjusted qualitatively using the  
703 automatically generated and interactive “Quality” filter histogram to select what appeared to be  
704 specific dense signal while excluding faint puncta that appeared to be background signal. To  
705 ensure an accurate spot segmentation of the underlying puncta determined by size, the “Different  
706 Spots Sizes” selection was utilized. Within this setting, the “Local Contrast” tool was used. The  
707 corresponding histogram was manually adjusted to ensure each spot covered as much of the

708 puncta as possible. Spots were then rendered. Once optimal settings for each of these parameters  
709 were established for HA-MDGA1 and each of the four synaptic markers, a batched protocol to  
710 automate spots creation on every image was run. Despite efforts to minimize non-specific HA  
711 signal, some residual and dim HA puncta were still detected in WT samples (Fig. 1J). Therefore,  
712 the Imaris filter selection tool: “Intensity Max”, was applied, setting the reference value to the  
713 10% highest intensity spots on a HA-MDGA1 KI sample, and discarding spots with intensity  
714 values below the threshold, thereby allowing for a standardized level of comparison between  
715 samples. As expected, this processing resulted in comparatively less colocalizing spots in WT  
716 samples compared to the KI samples (Fig. 2). To determine the colocalization between HA-  
717 MDGA1 and synaptic marker spots, the Matlab extension “Spots Colocalize” was used. This  
718 extension determines colocalization between two or more spots found within a given length  
719 measured from the center of each spot. Because both HA-MDGA1 and synaptic marker puncta  
720 appeared at varying sizes, setting the colocalization parameter to consider only spots at or within  
721 0.3  $\mu$ m from the center of neighbouring puncta was found to be the most accurate. Spots  
722 colocalizations were reported as the number of discrete HA-MDGA1 spots colocalized with at  
723 least one spot of each corresponding synaptic marker per 100 square microns.

724

## 725 **Attempts to minimize artefacts in tagged protein quantification**

726 We found a variable amount of residual, punctate HA expression in CA1 in WT mice,  
727 which represented approximately 30% of the signal found in the HA-MDGA1 mice. For this  
728 reason, KI mice and WT counterparts were compared in all imaging experiments. In any case,  
729 our experience constitutes a cautionary note when characterizing the expression of tagged  
730 proteins using KI mice.

731

## 732 **Spine morphology measurements**

733 Images were acquired using super-resolution microscopy (N-SIM Microscope System,  
734 Nikon) in organotypic slice preparations at day in vitro (DIV) 7, after sparse transfection of  
735 MDGA1 and MDGA2 shRNAs or control shRNA together with GFP at DIV 1. For use with the  
736 available inverted microscope and oil-immersion objective lens, slices were fixed in 4% PFA/4%  
737 sucrose in PBS and washed 3  $\times$  with PBS. To amplify the GFP signal, slices were then blocked  
738 and permeabilized in 3% BSA in PBS containing 0.1% Triton X-100 (Sigma-Aldrich # T8787)

739 and stained with rabbit anti-GFP (2 µg/mL, Life Technologies, #A-11122) followed by washes  
740 in PBS-Tx and staining with Alexa 488-conjugated goat anti-rabbit (4 µg/mL, Life Technologies,  
741 #A11034). Slices were then mounted in SlowFade Gold (Life Technologies, #S36936) for  
742 imaging. Only dendrites in the top 20 µm of the slice were imaged. Some slices were further  
743 processed with an abbreviated SeeDB-based protocol (53) in an attempt to reduce spherical  
744 aberration, but no substantial improvement was seen. Images were acquired with a ×100 oil  
745 objective in 3D-SIM mode using supplied SIM grating (3D EX V-R ×100/1.49) and processed  
746 and reconstructed using supplied software (NIS Elements, Nikon). Morphological analysis was  
747 done on individual sections using ImageJ to perform geometric measurements on spines  
748 extending laterally from the dendrite. Spine neck widths were obtained from full width half-  
749 maximum measurements based on Gaussian fits of line profile plots (54). Neck length was  
750 measured from the base of the spine to the base of the head. Head diameter was measured  
751 perpendicular to the spine neck axis through the thickest part of the spine head, and diameter was  
752 obtained using full width tenth maximum (FWTM) measurements based on Gaussian fits to  
753 approximate manual head measurement.

754

755 **Protein Identification Using Reversed-phase Liquid Chromatography Electrospray  
756 Tandem Mass Spectrometry (LC-MS/MS)**

757 HA-tagged MDGA1 or MDGA2 were expressed in HEK293T (as described above) and  
758 two days post-transfection were released from the membrane by addition of phospholipase C  
759 (PLC). Briefly, for PLC treatment, transfected 293T cell monolayers were washed, and then  
760 incubated with 0.2U/ml PLC (Sigma-Aldrich, P7633) in Optimem for 2 hr at 37°C. Soluble  
761 MDGAs were purified from the cellular media with anti-HA antibodies (see above) and  
762 incubated with mouse brain P2 fractions (solubilized in 1% triton) overnight to identify  
763 interacting proteins. Pull-downs were separated on SDS-page gels and subjected to silver  
764 staining (Thermo Scientific, #24612). See Fig. 3A for more details. Post silver staining, the  
765 targeted gel bands were excised from a gel and subjected to in-gel tryptic digestion. Proteins in  
766 the gel band were reduced with 10 mM dithiothreitol in 25 mM ammonium bicarbonate at 56°C  
767 for 1 hr, followed by alkylation with 55 mM iodoacetamide in 25 mM ammonium bicarbonate at  
768 room temperature for 45 min in the dark. The samples were then incubated overnight at 37°C  
769 with 100 ng trypsin (sequence grade, Promega). The peptides formed from the digestion were

770 further purified by  $\mu$ C18 ZipTips (Millipore) and resuspended in 0.1% formic acid in HPLC  
771 water.

772

773 The LC-MS/MS analyses were conducted by either a Velos Pro Elite Orbitrap (Elite)  
774 Mass Spectrometer or a LTQ Orbitrap Velos (Velos) mass spectrometer (Thermo Scientific)  
775 coupled with a NanoAcquity UPLC system (Waters). During the LC separation, peptides were  
776 first loaded onto an Easy-Spray PepMap column (75  $\mu$ m x 15 cm, Thermo Scientific). Following  
777 the initial column equilibration in 98% A (0.1% formic acid in water) / 2% B (0.1% formic acid  
778 in acetonitrile) over 20 min, the concentration of the phase B was linearly increased from 2 –  
779 30% at a flow rate of 300 nL per min over 27 min. Then the phase B concentration was increased  
780 linearly from 30 – 50% sequentially in the next two min. The column was then re-equilibrated in  
781 98% A / 2% B over 11 min. After a survey scan in the Orbitrap, the top six most intensive  
782 precursor ions were fragmented by either collision-induced dissociation with the Elite or Higher-  
783 energy C-trap dissociation with the Velos. The acquired MS/MS raw data was converted into  
784 peaklists using an in-house software PAVA (55). The peaklists were then searched against the  
785 Uniprot Mus Musculus database (UniProtKB.2017.11.01) using Protein Prospector search engine  
786 (<http://prospector.ucsf.edu/prospector/mshome.htm>). Proteins with at least 1 unique peptide were  
787 reported.

788

789 Mass spectrometry experiments were repeated three independent times for each condition  
790 (control (GFP), MDGA1, and MDGA2). Proteins were considered binders if i) they were  
791 identified >1 experiment and ii) 0 peptides were identified in the control lanes. Binders are  
792 highlighted in yellow in Supplementary Table 1. Fig. 3B contains a shortened list of synaptic  
793 proteins of interest.

794

## 795 **Electrophysiology**

796 Hippocampal organotypic slice cultures were isolated from P6-8 rats, as described  
797 previously (56) and biolistically transfected at DIV1. Briefly, mixed plasmid DNA (50  $\mu$ g total)  
798 was coated on 1  $\mu$ M-diameter gold particles (Bio-Rad, 1652263) in 0.5 mM spermidine. The  
799 DNA was precipitated with 0.1 mM CaCl<sub>2</sub>, washed four times in ethanol (Sigma-Aldrich,  
800 459836) and coated onto PVC tubing (Bio-Rad, 1652441). The tubing was dried with N<sub>2</sub> gas,

801 and the DNA-coated gold particles were delivered to the slices with a Helios Gene Gun  
802 (BioRad). Equal amounts of plasmid DNA (when necessary) were coated to gold particles for  
803 excitatory and inhibitory recordings, respectively. Each plasmid expressed different fluorescent  
804 markers, and we only recorded from cells that expressed both GFP and mCherry signifying  
805 expression of both plasmids. Slices were maintained at 34°C with media changes every other  
806 day.

807

808 Dual whole-cell recordings from CA1 PNs were performed at DIV 7-9. Since biolistics  
809 results in sparsely transfected hippocampal PNs per slice, simultaneous recordings from both a  
810 transfected neuron and neighboring untransfected control neuron were collected. Synaptic  
811 responses were evoked by stimulating with a monopolar glass electrode filled with artificial  
812 cerebrospinal fluid (aCSF) in CA1 SR. Synaptic strength was calculated by comparing the  
813 difference in magnitude of the transfected cell to the non-transfected control cell recorded  
814 simultaneously. PNs were identified by morphology and location. The number of experiments  
815 (n) reported in the figure legends refer to the number of paired recordings. Membrane holding  
816 current, input resistance, and pipette series resistance were monitored throughout recording. All  
817 recordings were made at 20-25°C using glass patch electrodes filled with an internal solution  
818 consisting of 135 mM CsMeSO<sub>4</sub> (Sigma-Aldrich, C1426), 8 mM NaCl (Sigma-Aldrich, 7647-  
819 14-5), 10 mM HEPES, 0.3 mM EGTA (Sigma-Aldrich, E3889), 4 mM Mg-ATP (Sigma-Aldrich,  
820 A9187), 0.3 mM Na-GTP (Sigma-Aldrich, G8877), 5 mM QX-314 (Abcam, 5369-03-9), and 0.1  
821 mM spermine (Sigma-Aldrich, S2876), and an external solution containing 119 mM NaCl, 2.5  
822 mM KCl (Sigma-Aldrich, 60128), 4 mM MgSO<sub>4</sub> (Sigma-Aldrich, 63138), 4 mM CaCl<sub>2</sub>, 1 mM  
823 NaH<sub>2</sub>PO<sub>4</sub> (Sigma-Aldrich, S9638), 26.2 mM NaHCO<sub>3</sub> (Sigma-Aldrich, S8875) and 11 mM  
824 glucose (Sigma-Aldrich, G8270) bubbled continuously with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. Excitatory  
825 recordings were made in the presence of 100 µM picrotoxin (TCI, C0375) to block inhibitory  
826 currents and a small (50 nM) amount of NBQX (abcam, ab120046) to reduce epileptiform  
827 activity at -70 mV (AMPA). Inhibitory recordings were made in the presence of 100 µM D-APV  
828 (Alomone Labs, D-145) and 10 µM NBQX to block NMDA receptor (NMDAR)- and AMPAR-  
829 mediated currents, respectively, at 0 mV. AMPAR- and IPSC-mediated currents were measured  
830 at the peak of the current. Investigator was blinded to the control vs. experimental group during  
831 data analysis. For more details see (47).

832 **Statistics**

833 Graph Pad Prism 9 was used for analyses of statistical significance and outliers.

834 Statistical significance of immunoblots was tested using a Mann-Whitney U test. Paired whole-

835 cell recordings were analyzed with a Wilcoxon signed-rank test. Unpaired Student's T-Test, and

836 one- or two-way ANOVA followed by Tukey's post hoc test for multiple comparisons were used

837 as appropriate to compare experimental groups in synaptic colocalization analyses. For the

838 confocal HA-vGluT1 colocalization analysis (Fig. 2G, H), three HA-MDGA1 brains were

839 excluded as image acquisition settings for those samples were found to not match those of the

840 rest of the samples analysed. All data are presented as mean  $\pm$  SEM.

841 **References**

842

- 843 1. T. Bourgeron, From the genetic architecture to synaptic plasticity in autism spectrum disorder. *Nature reviews. Neuroscience* **16**, 551-563 (2015).
- 844 2. J. Chen, S. Yu, Y. Fu, X. Li, Synaptic proteins and receptors defects in autism spectrum disorders. *Frontiers in cellular neuroscience* **8**, 276 (2014).
- 845 3. J. A. Chen, O. Penagarikano, T. G. Belgard, V. Swarup, D. H. Geschwind, The emerging 846 picture of autism spectrum disorder: genetics and pathology. *Annu Rev Pathol* **10**, 111- 847 144 (2015).
- 848 4. M. A. Bemben, S. L. Shipman, R. A. Nicoll, K. W. Roche, The cellular and molecular 849 landscape of neuroligins. *Trends Neurosci* **38**, 496-505 (2015).
- 850 5. T. C. Sudhof, Towards an Understanding of Synapse Formation. *Neuron* **100**, 276-293 851 (2018).
- 852 6. T. Biederer, P. S. Kaeser, T. A. Blanpied, Transcellular Nanoalignment of Synaptic 853 Function. *Neuron* **96**, 680-696 (2017).
- 854 7. M. Bucan *et al.*, Genome-wide analyses of exonic copy number variants in a family- 855 based study point to novel autism susceptibility genes. *PLoS genetics* **5**, e1000536 856 (2009).
- 857 8. A. K. Kahler *et al.*, Association analysis of schizophrenia on 18 genes involved in 858 neuronal migration: MDGA1 as a new susceptibility gene. *Am J Med Genet B* 859 *Neuropsychiatr Genet* **147B**, 1089-1100 (2008).
- 860 9. J. Li *et al.*, The MDGA1 gene confers risk to schizophrenia and bipolar disorder. 861 *Schizophr Res* **125**, 194-200 (2011).
- 862 10. C. De Juan *et al.*, Genomic organization of a novel glycosylphosphatidylinositol MAM 863 gene expressed in human tissues and tumors. *Oncogene* **21**, 3089-3094 (2002).
- 864 11. E. D. Litwack, R. Babey, R. Buser, M. Gesemann, D. D. O'Leary, Identification and 865 characterization of two novel brain-derived immunoglobulin superfamily members with a 866 unique structural organization. *Molecular and cellular neurosciences* **25**, 263-274 (2004).
- 867 12. K. L. Pettem, D. Yokomaku, H. Takahashi, Y. Ge, A. M. Craig, Interaction between 868 autism-linked MDGAs and neuroligins suppresses inhibitory synapse development. *The* 869 *Journal of cell biology* **200**, 321-336 (2013).
- 870 13. K. H. Loh *et al.*, Proteomic Analysis of Unbounded Cellular Compartments: Synaptic 871 Clefts. *Cell* **166**, 1295-1307 e1221 (2016).
- 872 14. S. A. Connor *et al.*, Altered Cortical Dynamics and Cognitive Function upon 873 Haploinsufficiency of the Autism-Linked Excitatory Synaptic Suppressor MDGA2. 874 *Neuron* **91**, 1052-1068 (2016).
- 875 15. A. Toledo *et al.*, MDGAs are fast-diffusing molecules that delay excitatory synapse 876 development by altering neuroligin behavior. *eLife* **11**, (2022).
- 877 16. S. A. Connor, J. Elegeert, Y. Xie, A. M. Craig, Pumping the brakes: suppression of 878 synapse development by MDGA-neuroligin interactions. *Curr Opin Neurobiol* **57**, 71-80 879 (2019).
- 880 17. K. Lee *et al.*, MDGAs interact selectively with neuroligin-2 but not other neuroligins to 881 regulate inhibitory synapse development. *Proceedings of the National Academy of* 882 *Sciences of the United States of America* **110**, 336-341 (2013).
- 883
- 884

885 18. J. Kim *et al.*, MDGA1 negatively regulates amyloid precursor protein-mediated synapse  
886 inhibition in the hippocampus. *Proceedings of the National Academy of Sciences of the*  
887 *United States of America* **119**, (2022).

888 19. T. Ishikawa *et al.*, IgSF molecule MDGA1 is involved in radial migration and positioning  
889 of a subset of cortical upper-layer neurons. *Dev Dyn* **240**, 96-107 (2011).

890 20. S. A. Connor *et al.*, Loss of Synapse Repressor MDGA1 Enhances Perisomatic  
891 Inhibition, Confers Resistance to Network Excitation, and Impairs Cognitive Function.  
892 *Cell reports* **21**, 3637-3645 (2017).

893 21. J. W. Um, J. Ko, Neural Glycosylphosphatidylinositol-Anchored Proteins in Synaptic  
894 Specification. *Trends Cell Biol* **27**, 931-945 (2017).

895 22. J. Elegheert *et al.*, Structural Mechanism for Modulation of Synaptic Neuroligin-  
896 Neurexin Signaling by MDGA Proteins. *Neuron* **95**, 896-913 e810 (2017).

897 23. S. P. Gangwar *et al.*, Molecular Mechanism of MDGA1: Regulation of Neuroligin  
898 2:Neurexin Trans-synaptic Bridges. *Neuron* **94**, 1132-1141 e1134 (2017).

899 24. J. A. Kim *et al.*, Structural Insights into Modulation of Neurexin-Neuroligin Trans-  
900 synaptic Adhesion by MDGA1/Neuroligin-2 Complex. *Neuron* **94**, 1121-1131 e1126  
901 (2017).

902 25. J. Kim, L. E. G. Wulschner, W. C. Oh, J. Ko, Trans-synaptic mechanisms orchestrated by  
903 mammalian synaptic cell adhesion molecules. *Bioessays* **44**, e2200134 (2022).

904 26. M. Wu *et al.*, Impairment of Inhibitory Synapse Formation and Motor Behavior in Mice  
905 Lacking the NL2 Binding Partner LHFPL4/GARLH4. *Cell reports* **23**, 1691-1705  
906 (2018).

907 27. T. C. Sudhof, The cell biology of synapse formation. *The Journal of cell biology* **220**,  
908 (2021).

909 28. R. Araya, J. Jiang, K. B. Eisenthal, R. Yuste, The spine neck filters membrane potentials.  
910 *Proceedings of the National Academy of Sciences of the United States of America* **103**,  
911 17961-17966 (2006).

912 29. J. Noguchi, M. Matsuzaki, G. C. Ellis-Davies, H. Kasai, Spine-neck geometry determines  
913 NMDA receptor-dependent Ca<sup>2+</sup> signaling in dendrites. *Neuron* **46**, 609-622 (2005).

914 30. A. S. Ravi *et al.*, Long-term potentiation reconstituted with an artificial TARP/PSD-95  
915 complex. *Cell reports* **41**, 111483 (2022).

916 31. M. A. Bemben *et al.*, CaMKII phosphorylation of neuroligin-1 regulates excitatory  
917 synapses. *Nature neuroscience* **17**, 56-64 (2014).

918 32. K. Goel, J. E. Ploski, RISC-y Business: Limitations of Short Hairpin RNA-Mediated  
919 Gene Silencing in the Brain and a Discussion of CRISPR/Cas-Based Alternatives. *Front*  
920 *Mol Neurosci* **15**, 914430 (2022).

921 33. S. Incontro, C. S. Asensio, R. H. Edwards, R. A. Nicoll, Efficient, complete deletion of  
922 synaptic proteins using CRISPR. *Neuron* **83**, 1051-1057 (2014).

923 34. S. S. Margolis *et al.*, EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a  
924 developmental brake on excitatory synapse formation. *Cell* **143**, 442-455 (2010).

925 35. Z. P. Wills *et al.*, The nogo receptor family restricts synapse number in the developing  
926 hippocampus. *Neuron* **73**, 466-481 (2012).

927 36. P. Y. Lin *et al.*, Neurexin-2: An inhibitory neurexin that restricts excitatory synapse  
928 formation in the hippocampus. *Sci Adv* **9**, eadd8856 (2023).

929 37. E. S. Lein *et al.*, Genome-wide atlas of gene expression in the adult mouse brain. *Nature*  
930 **445**, 168-176 (2007).

931 38. E. C. Budreck, P. Scheiffele, Neuroligin-3 is a neuronal adhesion protein at GABAergic  
932 and glutamatergic synapses. *The European journal of neuroscience* **26**, 1738-1748  
933 (2007).

934 39. P. Penzes, M. E. Cahill, K. A. Jones, J. E. VanLeeuwen, K. M. Woolfrey, Dendritic spine  
935 pathology in neuropsychiatric disorders. *Nature neuroscience* **14**, 285-293 (2011).

936 40. K. B. Hansen *et al.*, Structure, function, and allosteric modulation of NMDA receptors. *J  
937 Gen Physiol* **150**, 1081-1105 (2018).

938 41. J. Diaz-Alonso *et al.*, Subunit-specific role for the amino-terminal domain of AMPA  
939 receptors in synaptic targeting. *Proceedings of the National Academy of Sciences of the  
940 United States of America* **114**, 7136-7141 (2017).

941 42. J. F. Watson, H. Ho, I. H. Greger, Synaptic transmission and plasticity require AMPA  
942 receptor anchoring via its N-terminal domain. *eLife* **6**, (2017).

943 43. C. H. Jiang, M. Wei, C. Zhang, Y. S. Shi, The amino-terminal domain of GluA1 mediates  
944 LTP maintenance via interaction with neuroplastin-65. *Proceedings of the National  
945 Academy of Sciences of the United States of America* **118**, (2021).

946 44. J. Diaz-Alonso, R. A. Nicoll, AMPA receptor trafficking and LTP: Carboxy-termini,  
947 amino-termini and TARPs. *Neuropharmacology* **197**, 108710 (2021).

948 45. M. Bhouri *et al.*, Deletion of LRRTM1 and LRRTM2 in adult mice impairs basal AMPA  
949 receptor transmission and LTP in hippocampal CA1 pyramidal neurons. *Proceedings of  
950 the National Academy of Sciences of the United States of America* **115**, E5382-E5389  
951 (2018).

952 46. C. Francks *et al.*, LRRTM1 on chromosome 2p12 is a maternally suppressed gene that is  
953 associated paternally with handedness and schizophrenia. *Molecular psychiatry* **12**, 1129-  
954 1139, 1057 (2007).

955 47. M. A. Bemben *et al.*, Isoform-specific cleavage of neuroligin-3 reduces synapse strength.  
956 *Molecular psychiatry* **24**, 145-160 (2019).

957 48. J. Diaz-Alonso *et al.*, Long-term potentiation is independent of the C-tail of the GluA1  
958 AMPA receptor subunit. *eLife* **9**, (2020).

959 49. L. Chen *et al.*, Physiological activation of synaptic Rac-PAK (p-21 activated kinase)  
960 signaling is defective in a mouse model of fragile X syndrome. *J Neurosci* **30**, 10977-  
961 10984 (2010).

962 50. R. Seese *et al.*, LTP induction translocates cortactin at distant synapses in wild-type but  
963 not Fmr1 knock-out mice. *J Neurosci* **32**, 7403-7413 (2012).

964 51. C. Rex *et al.*, Different Rho GTPase-dependent signaling pathways initiate sequential  
965 steps in the consolidation of long-term potentiation. *J Cell Biol.* **186**, 85-97 (2009).

966 52. L. Chen, C. Rex, M. Casale, C. Gall, G. Lynch, Changes in synaptic morphology  
967 accompany actin signaling during LTP. *J Neurosci* **27**, 5363-5372 (2007).

968 53. M. T. Ke, S. Fujimoto, T. Imai, SeeDB: a simple and morphology-preserving optical  
969 clearing agent for neuronal circuit reconstruction. *Nature neuroscience* **16**, 1154-1161  
970 (2013).

971 54. J. Tonnesen, G. Katona, B. Rozsa, U. V. Nagerl, Spine neck plasticity regulates  
972 compartmentalization of synapses. *Nature neuroscience* **17**, 678-685 (2014).

973 55. S. Guan, J. C. Price, S. B. Prusiner, S. Ghaemmaghami, A. L. Burlingame, A data  
974 processing pipeline for mammalian proteome dynamics studies using stable isotope  
975 metabolic labeling. *Mol Cell Proteomics* **10**, M111 010728 (2011).

976 56. L. Stoppini, P. A. Buchs, D. Muller, A simple method for organotypic cultures of nervous  
977 tissue. *Journal of neuroscience methods* **37**, 173-182 (1991).  
978

979 **Acknowledgements**

980

981 We would like to thank Eric Dang, Dan Qin and Ananth V. Kolli for excellent technical  
982 assistance and members of the Nicoll and Diaz Alonso lab for helpful comments throughout the  
983 project. Funding sources: K99/R00 MH118425, BBRF Young Investigator Award 30264 and  
984 UCI Institutional funding to J.D.-A., R01 MH117139 and R01 MH070957 to R.A.N. and R01  
985 HD101642 to C.M.G. Mass Spectrometry of this work was provided by the Mass Spectrometry  
986 Resource at UCSF (A.L. Burlingame, Director) supported by the Dr. Miriam and Sheldon G.  
987 Adelson Medical Research Foundation (AMRF).

988

989 **Author contributions**

990

991 M.A.B., M.S., A.A.L., S.W., V.N.C., J. L., S.I., K.H.L. and J.D.-A., performed experiments;  
992 M.A.B., M.S., A.A.L., S.W., V.N.C., J. L., S.I., K.H.L., A.L.B., K.R., C.M.G., R.A.N and J.D.-  
993 A. analyzed data; M.A.B., J.D.-A. and R.A.N designed research; M.A.B., M.S., J. L., C.M.G.,  
994 R.A.N and J.D-A drafted and all authors commented on the manuscript and R.A.N. and J.D.-A.  
995 coordinated research.

996

997 **Competing interests**

998

999 Authors declare that they have no competing interests.

1000

1001 **Data and materials availability**

1002

1003 All data needed to reproduce and evaluate the conclusions of the study are present in the paper,  
1004 including the supplementary materials. Materials will be available upon completion of the  
1005 appropriate MTAs.